|
|
|
|
 |
|||
|
|||
Volume 52 (2): 253-261, 2004
Copyright ©The Histochemical Society, Inc.
Generation and Characterization of Anti-MUC4 Monoclonal Antibodies Reactive with Normal and Cancer Cells in Humans
Department of Biochemistry and Molecular Biology and Eppley Institute for Research in Cancer and Allied Disease, University of Nebraska Medical Center, Omaha, Nebraska (NM,GCV,SCC,MJ,UAW,MA,SKB); Institute of Microbial Technology, Chandigarh, India (GCV); and Unité INSERM 560, Lille, France (MCC,JPA)
Correspondence to: Surinder K. Batra, PhD, Dept. of Biochemistry and Molecular Biology, Eppley Inst. for Research in Cancer and Allied Diseases, U. of Nebraska Medical Center, 984525 Nebraska Medical Center, Omaha, NE 68198–4525. E-mail: sbatra{at}unmc.edu
 |
Summary |
|---|
 Top Summary IntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
We have previously cloned the full-length cDNA (approximately 28 Kb) and established the complete genomic organization (25 exons/introns over 100 kb) of the human MUC4 mucin. This large molecule is predicted to protrude over 2 µm above the cell surface, in which MUC4
is an extracellular mucin-type glycoprotein subunit and MUC4ß is the transmembrane subunit. Over two thirds of the encoded protein sequence consists of 16-amino-acid tandem repeats (TR), which are flanked by unique sequences. In this study we generated and characterized monoclonal antibodies (MAbs) directed against the TR region of MUC4. Mice were immunized with a KLH-conjugated MUC4 TR peptide, STGDTTPLPVTDTSSV. Several clones were purified by three rounds of limited dilutions and stable clones presenting a sustained antibody production were selected for subsequent characterization. Antibodies were tested for their reactivity and specificity to recognize the MUC4 peptide and further screened by enzyme-linked immunosorbent assay (ELISA) and Western blotting analyses. One of the MAbs (8G7) was strongly reactive against the MUC4 peptide and with native MUC4 from human tissues or pancreatic cancer cells in Western blotting, immunohistochemistry, and confocal analysis. Anti-MUC4 MAb may represent a powerful tool for the study of MUC4 function under normal and pathological conditions and for diagnosis of solid tumors including those in the breast, pancreas, lungs, and ovaries. (J Histochem Cytochem 52:253–261, 2004)
Key Words: mucin • MUC4 • antibody • pancreatic adenocarcinoma
|
Introduction |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
MUC4 is a high molecular weight O-glycoprotein belonging to the membrane-anchored mucin family (Moniaux et al. 2001
). It is a complex molecule, with a gene located on chromosome 3 in the q29 region (Porchet et al. 1991a) that codes for a family of 25 alternatively spliced transcripts (Choudhury et al. 2000a,2001; Moniaux et al. 2000). The main variant of MUC4 mRNA is known to be 27 kb in size and encodes a 930-kD protein composed of an 850-kD mucin-type subunit, MUC4, and an 80-kD membrane-bound subunit, MUC4ß (Moniaux et al. 1999). Approximately two thirds of the MUC4 protein sequence consists of identical 16-amino-acid tandem repeats (TR). MUC4ß has a growth factor-like structure. It is organized in modules, such as a cysteine-rich domain of an unknown signature, a domain rich in N-glycosylation sites, and three EGF-like domains. One potential tyrosine phosphorylation site is located in the small 22-amino-acid cytoplasmic tail.
The MUC4 mucin is the homologue of rat sialomucin complex (SMC, rat Muc4) owing to similarities in structural organization. However, rat Muc4 lacks the central domain containing the 16-amino-acid TR units found in human MUC4 (Sheng et al. 1992; Wu et al. 1994). Expression of MUC4 is detected in various epithelial tissues, including the trachea, colon, stomach, cervix, and lung (Audie et al. 1993,1995). MUC4 is detected in goblet, ciliated, and absorptive cells in adults but also in poorly differentiated cells in embryos and fetuses (Buisine et al. 1998,1999). The primitive gut expresses MUC4 at an early stage, before respiratory and digestive epithelial cells have acquired their tissue and cell specificity. However, an abnormal expression of MUC4 has been reported in various carcinomas of the colon, pancreas, breast, and ovaries (Andrianifahanana et al. 2001; Ogata et al. 1992). For example, MUC4 is highly expressed in the vast majority of human pancreatic tumors and pancreatic tumor cell lines but is not detected in the normal pancreas or in chronic pancreatitis (Balague et al. 1994; Hollingsworth et al. 1994; Choudhury et al. 2000a; Andrianifahanana et al. 2001). Likewise, MUC4 is expressed by metasplastic ducts and its expression increases with a higher grade in pancreatic intraepithelial neoplasias (PanINs) (Swart et al. 2002; Park et al. 2003).
The rat Muc4 has been shown to act as a ligand for the receptor tyrosine kinase ErbB2/HER2/neu (Carraway et al. 1999), and its expression in human melanoma cells resulted in lung metastasis in a mouse model (Komatsu et al. 2000). Because of the MUC4 homology to rat Muc4 and its unique pattern of expression in human fetal and tumor tissues, it is believed that MUC4 plays a crucial role in development and tumorigenesis. However, no direct evidence is available to validate these hypotheses. One of the main reasons for this poor understanding is the lack of a specific antibody recognizing the human MUC4 molecule.
To generate unique molecular tracers of human MUC4, mice were immunized by repeated IP injections of a KLH-conjugated MUC4 peptide. Splenocytes were fused with NS-1 myeloma cells to generate hybridomas. Antibodies were screened against MUC4 peptides and native protein by enzyme-linked immunosorbent assay (ELISA) and immunoblotting. One of the MAbs, 8G7, was strongly reactive against the MUC4 peptide and was used to investigate native MUC4 expression in tissue samples and cell lines by Western blotting, immuhistochemistry (IHC), and confocal analysis. MAb 8G7 recognized a very high molecular weight protein, well over 500 kD, which was the expected size for native MUC4 (Moniaux et al. 1999; Choudhury et al. 2000a). Moreover, the pattern of expression of MUC4 in 15 pancreatic adenocarcinoma cell lines, as detected by 8G7, paralleled MUC4 expression as revealed by RT-PCR and Northern blotting analyses of cell lines (Andrianifahanana et al. 2001; Choudhury et al. 2000a). The size of the MUC4 protein was cell line-specific and exhibited a direct correlation with the MUC4 allelic variation previously reported using Southern blotting (Choudhury et al. 2000a). MAb 8G7 was also able to immunoprecipitate MUC4 and to recognize MUC4 by IHC and confocal analyses. In the latter case, MUC4 was expressed on the surface membrane of the cells.
Altogether, this work presents the generation and characterization of important MAbs that specifically target the complete human high molecular weight MUC4 mucin and could be a powerful tool for study of MUC4 function and for diagnosis of adenocarcinomas.
|
Materials and Methods |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
Materials
The peptides used in this study were designed according to the deduced amino acid sequence from the clone JER64, isolated and characterized earlier with accession number M64594 (Porchet et al. 1991b
). Two peptides were synthesized (Invitrogen; Carlsbad, CA), a 16-amino-acid peptide STGDTTPLPVTDTSSV, called 16TR, and an 8-amino-acid peptide GDTTPLPV, called 8TR.
Mouse Immunization
The immunization and selection of MAbs were carried out using established procedures at the UNMC Hybridoma Core Facility. Briefly, mice were immunized by repeated IP injections of KLH-conjugated MUC4 peptide (16TR) at 2-week intervals. Sera from these mice were evaluated in direct binding assays for antibody reactivity with MUC4 peptide and protein lysate from the MUC4-expressing CD18/HPAF cell line. KLH was used as a negative control. Once an appropriate antibody response was noted, as determined by reciprocal 50% end point titers in excess of 5000 vs antigen, the animals were given a final booster injection 3 or 4 days before splenectomy and exsanguination. Splenocytes were isolated and fused with NS-1 and/or Sp2/0 myeloma cells. Hybridomas producing the antibodies of interest were selected by screening for specific antibody binding to the immunogen of interest and lack of binding to irrelevant control antigens.
Screening of the MUC4-positive Hybridomas
Supernatants from different hybridomas were screened by ELISA using KLH- and MUC4 peptide-coated 96-well plates. Cells from the positive wells were further cloned three additional times. For the ELISA, plates were coated with 100 µl/well of MUC4 peptide or KLH at a concentration of 10 µg/ml in freshly prepared bicarbonate buffer by incubation for 2 hr at 37C. After several washes in PBS, 100 µl of the test supernatant was incubated for 6 hr at room temperature (RT), which was followed by several washes in PBS. Plates were further incubated with a 1:12,000 dilution of anti-mouse Ig conjugated to alkaline phosphatase for 45 min at 37C. At the end, plates were washed and bound antibody was detected using (p-nitrophenylphosphate) the Phosphatase Substrate System (Kirkegaard & Perry Laboratories; Gaithersburg, MD) as recommended by the supplier.
For the competitive ELISA, MAbs were pre-incubated overnight at 4C with 1 µg/ml of MUC4 peptide 16TR or 8TR. PBS was used as a negative control. After the incubations, the reactivity of the MAbs was checked by ELISA on 16TR-coated plates as described above.
Isotyping of the purified MAbs was performed using the mouse MAb isotyping kit code RPN 29 (Amersham Pharmacia Biotech; Piscataway, NJ).
Preparation of Cell Lysates and Immunoblotting
Cell lysates were prepared in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 µg/ml of aprotinin and leupeptin, 1 mM Na3VO4, and 1 mM NaF). The protein content of the lysates was determined by the Bio-Rad DC protein assay (Bio-Rad; Hercules, CA) as recommended by the supplier.
For immunoprecipitation, MAb 8G7 was used at a concentration of 4 µg/ml with 500 µl of cell lysate (prepared from one confluent T75 flask of cells in 1 ml of RIPA buffer). After an overnight incubation at 4C on a shaker, 40 µl (1:1 v/v in lysis buffer) of protein G–sepharose beads (Sigma; St Louis, MO) was added to the mixture. The beads were pelleted by centrifugation, washed twice with a buffer of 50 mM Tris containing 500 mM NaCl, followed by a final wash in 50 mM Tris, and boiled in sample loading buffer (2% SDS, 62.5 mM Tris-HCl, pH 6.8, 5% glycerol, 2% mercaptoethanol, and 0.01% bromophenol blue) for loading on SDS–Agarose gels and Western analysis.
Cell lysates or immunoprecipitates were resolved on a 0.1% sodium dodecyl sulfate (SDS)-2% agarose gel electrophoresis (AGE), transferred to polyvinylidene difluoride (PVDF) membranes, and the membrane were blocked in 5% non-fat dry milk in PBS for 1 hr. Membranes were incubated for 4 hr at RT with the test or control antibodies diluted at 1 µg/ml in PBS, followed by six 10-min washes in TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween-20). Horseradish peroxidase-conjugated secondary antibodies were diluted at 1:2000 in PBS and incubated for 1 hr at RT. Three washes in TBST followed secondary antibody incubation. Membranes were developed using ECL Western blotting detection reagents (Amersham Life Science) and blots were exposed to ECL-sensitive film (Eastman Kodak; Rochester, NY).
Phosphoglycerate kinase (PGK) was used as a protein-loading control for Western blotting analysis. The immunoblotting procedures were carried out according to the conventional SDS-PAGE Western blotting method (Laemmli 1970).
Confocal Analysis
Cells were grown at a low density on sterilized coverslips for 20 hr. Cells were washed with 0.1 M HEPES containing Hanks buffer and fixed in ice-cold methanol at -20C for 2 min. Methanol-fixed cells were blocked in 10% goat serum containing 0.05% Tween-20 for 30 min at RT before incubation with 8G7 primary antibody diluted (1:100) in 10% goat serum containing PBS for 60 min at RT. Cells were washed four times for 5 min with PBS containing 0.05% Tween-20 and then incubated with FITC-conjugated goat anti-mouse secondary antibodies (Jackson Immuno Research laboratories; West Grove, PA) for 60 min at RT. Cells were again washed with PBS–Tween five times for 5 min and once in water before mounting on a glass slide in anti-fade VECTASHIELD mounting medium (Vector Laboratories; Burlingame, CA). Immunostaining was observed under a Zeiss Laser Scan confocal microscope (Zeiss; Oberkochen, Germany).
Immunohistochemical Analysis
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections (5 µm) were assayed for MUC4 apomucin by using a modification of the previously described ABC IHC method (Pour et al. 1993; Batra et al. 1995). Briefly, tissue sections were deparaffinized in xylene, rehydrated in graded ethanol, and treated for 20 min with 0.3% H2O2/methanol to block endogenous peroxidase. The sections were blocked with normal goat serum for 1 hr followed by incubation at 4C overnight with 8G7 MAb or pre-immune rabbit serum as a negative control. The immunoreactivity and the specificity of the antibodies generated against the tandem repeat peptide was evaluated for the immunocytochemical procedure as previously described (Choudhury et al. 2000b).
|
Results |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
After cell fusion, screening, and cloning procedures, six clones secreting the anti-MUC4 antibody were selected, and one clone secreting the anti-KLH antibody was used as a negative control (Table 1) . None of the six MUC4-specific MAbs presented any reactivity against KLH. Two of the six MAbs, 13F12 and 8G7, showed strong reactivity to the MUC4 peptide. Mabs 9H8, 12B8, IG2, and 11A8 MAbs presented mild reactivity, whereas the 1G2 MAb showed low reactivity. Table 1 summarizes the respective isotypes of these antibodies, IgG2b(k) or IgG1(k).
|
The six anti-MUC4 MAbs were further tested against the linear concentration of synthetic MUC4 peptide (0.5–10 µg/ml per well). As shown in Figure 1A , the six antibodies differed in their respective titers to the 16TR peptide. The 13F12 and 8G7 MAbs presented the best reactivity compared to 1G2 and 11A8. The K2G6 anti-KLH MAb did not show any reactivity.
|
ELISA was performed to check the specificity of each antibody for different mucins. Mucins share the common property of being rich in serine and threonine residues, which are mainly concentrated in the central domain of the molecules. Specifically, the central domain of mucins is composed of tandemly repeated units, and the number can reach up to 400 in the case of MUC4. To check the specificity of MUC4 MAbs and to investigate any potential crossreactivity with other mucins, anti-MUC4 MAbs were analyzed against the 16TR MUC4 peptide, a 100-amino-acid MUC1 peptide (Hiltbold et al. 1998
) and purified MUC1 and MUC4, as described previously (Khorrami et al. 2002). The results are shown in Figure 1B. The anti-KLH MAb was used as a negative isotype control. As previously described, six anti-MUC4 MAbs reacted against the 16TR peptide. None of the MUC4 MAbs reacted against the MUC1 peptide or the native MUC1 protein. MAbs had a distinct reactivity toward MUC4 native protein, however, with MAb 8G7 and 1G2 exhibiting the strongest binding, whereas MAb 11A8 showed mild reactivity and MAbs 12B8, 13F12, and 9H8 showed low reactivity. Despite the strong recognition of the 16TR, some MAbs (11A8, 12B8, 13F12, 9H8) reacted weakly with the native protein in ELISA. Therefore, 8G7 and 1G2 appeared promising in their ability to recognize the native MUC4. To determine if the MAbs were recognizing the same epitope within the 16TR, each MAb was tested by competitive ELISA, using the 16TR and the 8TR peptides (Figure 2) . The 8TR was designed within the 16TR and defined as the sequence less likely to be O-glycosylated using the NetOGlyc 3.0 software (http://www.cbs.dtu.dk/services/NetOGlyc-3.0/). The two longest underglycosylated stretches of sequences, located between amino acids 2–6 and 6–11 with the threonine in position 6, presented a 98% chance to be glycosylated. The reactivity of all MAbs, with the exception of negative control MAb K2G6 (anti-KLH), was completely inhibited by the 16TR. On the other hand, reactivity of only the 1G2 MAb was completely inhibited by the 8TR (Figure 2). Therefore, the epitope of 1G2 appears to be distinct from that recognized by the other MAbs.
|
Because antibodies can present a distinct reactivity between ELISA and Western blotting, six MAbs were also tested for their ability to recognize the MUC4 protein in Western blotting. Mucins are high molecular weight proteins that cannot be resolved by traditional SDS-PAGE. For example, MUC1, which is one of the smallest mucins, varies in size between 250 and 1000 kD, depending on the allele and its level of glycosylation (Lan et al. 1987
; Shimizu and Yamauchi 1982). MUC4, which is the largest human mucin fully characterized thus far, has an expected size, without any glycosylation, of 930 kD (Moniaux et al. 1999; Choudhury et al. 2000a). To resolve such high molecular weight proteins, the strategy of 2% AGE was chosen. Protein lysates (30 µg of protein/well) from the MUC4-expressing human pancreatic tumor cell line (CD18/HPAF) were resolved on an agarose gel. Under these conditions, the 250-kD size marker protein (myosin) (BioRad) migrated at 1 cm from the bottom of a 15-cm (6-inch) gel. Western blotting analysis of various anti-MUC4 antibodies is shown in Figure 3
. MAb 8G7, at a concentration of 1 µg/ml, presented the highest reactivity, with a high molecular weight band resolved at the top of the gel. The 1G2 detected native MUC4 with 50% less intensity. The MAbs 13F12 and 11A8 presented a weak signal. Other MAbs, 9H8 and 12B8, reacted in Western blotting with a very strong background. Increasing the antibody concentration to 10 µg/ml did not have any effect on the signal (data not shown). Therefore, the concentration of 1 µg/ml of MAb was used for further investigations. To solve the background problem associated with 9H8 and 12B8, all MAbs were assayed using a nitrocellulose membrane, with different conditions of membrane blocking and primary MAb incubation buffers. All the conditions tested gave similar results (data not shown).
|
Overall, 8G7 was the best MAb specifically recognizing the MUC4 peptide as well as the MUC4 native protein in ELISA and Western blotting analyses. This MAb was used to investigate MUC4 protein expression in 15 different pancreatic cell lines (Figure 4 A1). PGK was used as a control to check the quality of the protein lysates. Once again, high molecular weight bands were detected in the upper part of the gel (over 500 kD). No band was detected for five cell lines, including MiaPaCa and Panc 1, that are known to be MUC4 non-expressing by RT-PCR (Figure 4A2) and Northern blotting (Andrianifahanana et al. 2001
), as well as AsPC1, Hs766T, and BxPC3 that express low levels of the MUC4 transcript (Andrianifahanana et al. 2001). One or two bands were detected for the other cell lines. The size of the bands detected showed a perfect correlation with the allelic VNTR polymorphism as previously detected by Southern blotting in the same cell lines (Choudhury et al. 2000a). For comparative purposes, the pattern of MUC4 expression investigated by RT-PCR on the same 15 pancreatic adenocarcinoma cell lines is presented in Figure 4A2. In addition, 8G7 was able to recognize native MUC4, as evidenced by data from Western blotting performed on tissue samples. MUC4 was detected in tracheal and pancreatic adenocarcinoma tissue samples, whereas the normal pancreas sample appeared negative for MUC4 expression (Figure 4B). In a similar way, 8G7 (at 4 µg/ml) was also able to immunoprecipitate the MUC4 protein from the CD18/HPAF lysate (Figure 4C).
|
IHC and confocal analyses were carried out to test the ability of 8G7 to recognize MUC4 using these techniques. Under a normal physiological situation, the main site of MUC4 expression is the respiratory tract (Audie et al. 1993
; Copin et al. 2000,2001). MUC4 is expressed by the trachea, the bronchus, throughout the bronchiole, and with a decreasing gradient of intensity from the trachea to the bronchiole. Figure 5A
shows MUC4 expression by airway epithelium using 8G7 MAb. Cells from the surface epithelium of the bronchiole appeared positive for MUC4 expression, whereas the surrounding pneumocytes were negative. In a similar way, Figure 5B shows MUC4 expression by a lung adenocarcinoma tissue sample, a tissue known to be MUC4-positive (Copin et al. 2001). A high level of staining was seen in a cancerous area in the pancreas (Figure 5C). The staining appeared concentrated in the cytoplasm of the cells, which is consistent with the secretory granules of that accumulate in the cytoplasm to be released in the mucus. The ratio of the membrane-bound:secreted form varies for MUC4 from tissue to tissue (Carraway et al. 2003).
|
Confocal microscopic analysis was performed on the MUC4-expressing CD18/HPAF cell line. In confluent monolayer cells, as predicted by the MUC4 structural organization, 8G7 MAb immunoreacted predominantly with the plasma membrane of CD18/HPAF cells and moderately with the cytoplasmic compartment (Figure 6) . The profile of expression was directly related to the membrane-bound expression of MUC4.
|
|
Discussion |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
MUC4 is a promising target for both diagnosis and therapeutic purposes in several tumor situations, most importantly pancreatic cancer (Andrianifahanana et al. 2001
). The lack of specific anti-MUC4 antibodies has limited our progress in many areas of MUC4 research, including an early diagnosis and targeted therapy. MUC4 belongs to the membrane-anchored mucins and is the largest member of this family (Moniaux et al. 1999,2001). It is a modular molecule composed of two non-covalently linked subunits, a large mucin-type subunit, MUC4, and a membrane-bound growth factor-like subunit, MUC4ß. The two subunits result from cleavage at a GDPH site of a unique 930-kD precursor.
The problem in obtaining antibodies to specifically target mucin proteins is related to their structure. Mucins are high molecular weigh O-glycoproteins composed of many glycan chains, up to 80% of their mass. The glycan chains, which are mainly carried by the hydroxyl amino acid of the mucin central domain, mask a large majority of the core protein epitopes. The main mucin-type antibodies available recognize glycan epitopes and therefore do not bind with a unique mucin. For example, the DU-PAN-2 antibody is reactive with MUC1 and MUC4 (Khorrami et al. 2002). In the present study, a 16-amino-acid sequence was chosen to generate specific MUC4 mouse MAbs. The peptide is located in the central domain of MUC4, which is composed of the same 16 amino acid residues repeated in tandem up to 400 times for the main MUC4 allele (Nollet et al. 1998).
The reactivity of the anti-MUC4 MAbs listed in Table 1 was established by multiple approaches but most critically by ELISA, competitive ELISA, purified native MUC4 protein, immunoprecipitation, and blotting of lysates from the MUC4-expressing pancreatic tumor lines. The lack of reactivity to MUC1 and other MUC4-non-expressing cell lines established the specificity of these MAbs for MUC4. Among the six clones isolated, the 8G7 MAb was reactive against the MUC4 peptide as well as the native protein. In Western blotting, 8G7 detected MUC4 expression with a pattern similar to that observed in RT-PCR analysis (Figures 4A1 and 4A2). MAb 8G7 binds to the -subunit of MUC4, which has a size of 850 kD. The fact that 8G7 recognized a very high molecular weight protein (well over 500 kD) in Western blotting under the conditions used (2% agarose/SDS gel) confirmed the specificity of binding to MUC4. Only mucins are reported to present such a molecular weight in epithelial cells. Moreover, the 2% agarose/SDS Western blotting technique enabled us to detect the MUC4 VNTR polymorphic allele with very good resolution. The size of MUC4 detected for each cell line was in full agreement with the VNTR of MUC4 gene previously reported (Choudhury et al. 2000a).
Importantly, the reactivity of 8G7 for the MUC4 native protein appeared to not be dependent on the level of glycosylation. The fact that 8G7 recognized the MUC4 protein in the tumor situation in Western blotting as well as in IHC analysis was anticipated because mucins are reported to be under-glycosylated in cancer. In confocal analysis, MUC4 was found expressed at the membrane surface of the cell, which is also consistent with the MUC4 structure. It should be noted, however, that 8G7 also recognized the MUC4 protein in normal tissue, such as the trachea in Western blotting (Figure 4B) or the normal bronchiole in IHC analysis.
In summary, six specific anti-MUC4 MAbs have been generated and two exhibit high avidity for a high molecular weight MUC4 native protein. One of the anti-MUC4 MAbs, 8G7, showed high specificity and avidity in ELISA, Western blotting, immunoprecipitation, and in IHC and confocal analyses for the MUC4 protein. Rat SMC (rMuc4), a homologue of human MUC4 because of its similar structural organization, is a heterodimeric glycoprotein complex composed of mucin (ascites sialoglycoprotein 1, ASGP-1) and transmembrane ASGP-2 subunits. ASGP-2 potentiates HER2 signaling and possesses a crossroad position between triggering the cells towards differentiation or proliferation via p27kip (for review see Carraway et al. 2002). Therefore, the MAb 8G7 would be an important tool for diagnostic applications and for understanding MUC4 interactions in human normal and cancer tissues.
|
Acknowledgments |
|---|
Supported by an RO1 grant CA78590 and a SPORE grant PA566A 72712 from the National Institutes of Health.
We thank Erik Moore for technical support and the Molecular Biology Core Facility, UNMC, for oligonucleotide synthesis and DNA sequencing, the Monoclonal Antibody Core facility, and Kristi L.W. Berger (Eppley Institute) for editorial assistance.
|
Footnotes |
|---|
1 These authors contributed equally to this work.
Received for publication June 27, 2003; accepted September 22, 2003
|
Literature Cited |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Buchler MW, et al. (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7:4033–4040
Audie JP, Janin A, Porchet N, Copin MC, Gosselin B, Aubert JP (1993) Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. J Histochem Cytochem 41:1479–1485[Abstract]
Audie JP, Tetaert D, Pigny P, Buisine MP, Janin A, Aubert JP, Porchet N, et al. (1995) Mucin gene expression in the human endocervix. Hum Reprod 10:98–102
Balague C, Gambus G, Carrato C, Porchet N, Aubert JP, Kim YS, Real FX (1994) Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology 106:1054–1061[Medline]
Batra SK, Castelino–Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6:1251–1259[Abstract]
Buisine MP, Devisme L, Copin MC, Durand–Reville M, Gosselin B, Aubert JP, Porchet N (1999) Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol 20:209–218
Buisine MP, Devisme L, Savidge TC, Gespach C, Gosselin B, Porchet N, Aubert JP (1998) Mucin gene expression in human embryonic and fetal intestine. Gut 43:519–524
Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M, Haq B, et al. (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acids Res Mol Biol 71:149–185[Medline]
Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA (2003) Cell signaling through membrane mucins. Bioessays 25: 66–71[Medline]
Carraway KL, Rossi EA, Komatsu M, Price–Schiavi SA, Huang D, Guy PM, Carvajal ME, et al. (1999) An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 274:5263–5266
Choudhury A, Moniaux N, Ringel J, King J, Moore E, Aubert JP, Batra SK (2001) Alternate splicing at the 3'-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratogen Carcinogen Mutagen 21:83–96[Medline]
Choudhury A, Moniaux N, Winpenny JP, Hollingsworth MA, Aubert JP, Batra SK (2000a) Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem (Tokyo) 128:233–243
Choudhury A, Singh RK, Moniaux N, El-Metwally TH, Aubert JP, Batra SK (2000b) Retinoic acid dependent transforming growth factor-beta2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway. J Biol Chem 275:33929–33936
Copin MC, Buisine MP, Leteurtre E, Marquette CH, Porte H, Aubert JP, Gosselin B, et al. (2001) Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol 32:274–281[Medline]
Copin MC, Devisme L, Buisine MP, Marquette CH, Wurtz A, Aubert JP, Gosselin B, et al. (2000) From normal respiratory mucosa to epidermoid carcinoma: expression of human mucin genes. Int J Cancer 86:162–168[Medline]
Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 58:5066–5070
Hollingsworth MA, Strawhecker JM, Caffrey TC, Mack DR (1994) Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer 57:198–203[Medline]
Khorrami AM, Choudhury A, Andrianifahanana M, Varshney GC, Bhattacharyya SN, Hollingsworth MA, Kaufman B, et al. (2002) Purification and characterization of a human pancreatic adenocarcinoma mucin. J Biochem (Tokyo) 131:21–29
Komatsu M, Tatum L, Altman NH, Carothers CC, Carraway KL (2000) Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. Int J Cancer 87:480–486[Medline]
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685[Medline]
Lan MS, Bast RCJ, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS (1987) Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer 39:68–72[Medline]
Moniaux N, Escande F, Batra SK, Porchet N, Laine A, Aubert JP (2000) Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 267:4536–4544[Medline]
Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK (2001) Structural organization and classification of the human mucin genes. Front Biosci 6:D1192–1206[Medline]
Moniaux N, Nollet S, Porchet N, Degand P, Laine A, et al. (1999) Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem J 338:325–333
Nollet S, Moniaux N, Maury J, Petitprez D, Degand P, Laine A, Porchet N, et al. (1998) Human mucin gene MUC4: organization of its 5'-region and polymorphism of its central tandem repeat array. Biochem J 332:739–748
Ogata S, Uehara H, Chen A, Itzkowitz SH (1992) Mucin gene expression in colonic tissues and cell lines. Cancer Res 52:5971–5978
Park HU, Kim JW, Kim GE, Bae HI, Crawley SC, Yang SC, Gum J Jr. et al. (2003) Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Lex antigen in pancreatic intraepithelial neoplasia. Pancreas 26:E48–54
Porchet N, Dufosse J, Audie JP, Duperat VG, Perini JM, Nguyen VC, Degand P, et al. (1991a) Structural features of the core proteins of human airway mucins ascertained by cDNA cloning. Am Rev Respir Dis 144:S15–18[Medline]
Porchet N, Nguyen VC, Dufosse J, Audie JP, Guyonnet-Duperat V, Gross MS, Denis C, et al. (1991b) Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem Biophys Res Commun 175:414–422[Medline]
Pour PM, Kazakoff K, Dulaney K (1993) A new multilabeling technique for simultaneous demonstration of different islet cells in permanent slides. Int J Pancreatol 13:139–142[Medline]
Sheng Z, Wu K, Carraway KL, Fregien N (1992) Molecular cloning of the transmembrane component of the 13762 mammary adenocarcinoma sialomucin complex. A new member of the epidermal growth factor superfamily. J Biol Chem 267:16341–16346
Shimizu M, Yamauchi K (1982) Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane. J Biochem (Tokyo) 91:515–524
Swart MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, Willentz RE, et al. (2002) MUC4 Expression increases progressively in pancreatic intraepithelial neoplasia (PanIN). Am J Clin Pathol 117:791–796[Medline]
Wu K, Fregien N, Carraway KL (1994) Molecular cloning and sequencing of the mucin subunit of a heterodimeric, bifunctional cell surface glycoprotein complex of ascites rat mammary adenocarcinoma cells. J Biol Chem 269:11950–11955
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Vincent, M.-P. Ducourouble, and I. Van Seuningen Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases FASEB J, August 1, 2008; 22(8): 3035 - 3045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Blalock, S. J. Spurr-Michaud, A. S. Tisdale, and I. K. Gipson Release of Membrane-Associated Mucins from Ocular Surface Epithelia Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1864 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chaturvedi, A. P. Singh, S. Chakraborty, S. C. Chauhan, S. Bafna, J. L. Meza, P. K. Singh, M. A. Hollingsworth, P. P. Mehta, and S. K. Batra MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells Cancer Res., April 1, 2008; 68(7): 2065 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chaturvedi, A. P. Singh, N. Moniaux, S. Senapati, S. Chakraborty, J. L. Meza, and S. K. Batra MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins Mol. Cancer Res., April 1, 2007; 5(4): 309 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Russo, S. Spurr-Michaud, A. Tisdale, J. Pudney, D. Anderson, and I. K. Gipson Mucin gene expression in human male urogenital tract epithelia Hum. Reprod., November 1, 2006; 21(11): 2783 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Koscinski, S. Viville, N. Porchet, A. Bernigaud, F. Escande, A. Defossez, and M.-P. Buisine MUC4 gene polymorphism and expression in women with implantation failure Hum. Reprod., September 1, 2006; 21(9): 2238 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Moniaux, W. M. Junker, A. P. Singh, A. M. Jones, and S. K. Batra Characterization of Human Mucin MUC17: COMPLETE CODING SEQUENCE AND ORGANIZATION J. Biol. Chem., August 18, 2006; 281(33): 23676 - 23685. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact |